Kornimate/medical-research-clean huggingface dataset:
interferon alfa and interleukin-6 in treating patients with recurrent multiple myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: interferon alfa may interfere with the growth of cancer cells. interleukin-6 may stimulate the white blood cells to kill cancer cells. giving interferon alfa together with interleukin-6 may kill more cancer cells. purpose: this clinical trial is studying the side effects and how well giving interferon alfa together with interleukin-6 works in treating patients with recurrent multiple myeloma.

objectives: * determine the response rate in patients with recurrent multiple myeloma treated with recombinant interferon alfa and recombinant interleukin-6. * determine the safety and optimal dose of this regimen in these patients. * determine the toxicity of this regimen in these patients. * determine the impact of this regimen on clonogenic growth of myeloma cells in serial in vitro assays. outline: this is a pilot study. patients receive recombinant interferon alfa subcutaneously (sc) once daily. beginning 1 month later, patients also receive recombinant interleukin-6 sc once daily. treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 27 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of recurrent multiple myeloma * must have received ≥ 2 prior therapies patient characteristics: * performance status 0-3 prior concurrent therapy: * see disease characteristics

Keywords: refractory multiple myeloma stage i multiple myeloma stage ii multiple myeloma stage iii multiple myeloma
exercise workshop, skill-based art approaches, and awareness studies for elderly individuals

Conditions: Mild Cognitive Impairment (MCI); Dementia; Alzheimer Disease; Geriatric Rehabilitation; Elderly (People Aged 65 or More)

Summary: purpose: the aim of the project is to contribute to the physical, social, and psychological well-being of elderly individuals with cognitive impairment within a multidisciplinary approach framework, and to increase the level of knowledge and awareness about diseases and aging by organizing exercise, art, and education workshops under the guidance of expert health and art professionals. scope and target group: cognitive impairment affects daily life activities by impacting cognitive abilities such as memory, attention, and concentration. mild cognitive impairment (mci), dementia, and alzheimer's disease (ad) are common cognitive impairments in the elderly. early prevention strategies and intervention measures during this period are crucial. it is known that non-pharmacological interventions, especially in the early stages of mci, are a window of opportunity that is promising and cost-effective. the primary target audience of this project is elderly individuals diagnosed with mci, dementia, and ad. to maximize the impact, some of the planned training sessions included family members of patients. method and expected results: the project carried out in collaboration with balıkesir university and balıkesir altıeylül municipality. various exercise and art workshops organized. workshop activities conducted for eight weeks and included an exercise workshop (music-based exercises, exercise with active video games, clinical pilates training, cognitive exercise therapy approach, nordic walking, dance therapy), skill-oriented art workshop (systemic calligraphy therapy, soap-candle making workshop, culinary arts workshop), and disease awareness studies (disease awareness information and education, the process from diagnosis to acceptance, experiences of patients and relatives, use of daily life technologies, home adjustments against falls, introduction of municipal services for the elderly).


Eligibility criteria:
inclusion criteria: * being over 65 years of age * having one of the diagnoses of mci, dementia, or alzheimer's by a neurologist or geriatrician * having less than 27 points on the mini mental state examination (zhuang et al., 2021). * being between stages 2-5 on the global impairment scale. exclusion criteria: * having a pulmonary, neurological, musculoskeletal, or rheumatological disease that may prevent exercise * having balance problems or lower extremity asymmetry at a level that may prevent exercise * individuals with unstable medical conditions (uncontrolled diabetes or hypertension, deep vein thrombosis, etc.) * having vision or hearing problems at a level that will prevent participation in workshops

Keywords: mild cognitive impairment dementia alzheimer&#39;s disease awareness workshop art exercise elderly health
entresto tablets and granules for pediatric specified drug-use survey (pediatric chronic heart failure)

Conditions: Pediatric Chronic Heart Failure

Summary: this is multicenter, single-arm, non-interventional, centrally enrolled specified drug-use survey to investigate the safety of entresto tablets or entresto granules for pediatric in pediatric patients with chronic heart failure in actual clinical settings for up to 52 weeks after administration.

this specified drug-use survey is conducted to collect information on the safety specifications of entresto in pediatric patients with chronic heart failure in japan in actual clinical settings, and to investigate the occurrence of events related to the safety specifications, the risk factors associated with these events, and the status of entresto administration including the accidental administration of capsule-shaped container (granules for pediatric). the subjects of this study are pediatric patients and a long-term observation of 1 year (52 weeks) has been set.

Eligibility criteria:
inclusion criteria 1. written informed consent by a legally acceptable representative must be obtained before the start of treatment with entresto. 2. patients who received entresto for the first time under the indication of chronic heart failure 3. pediatric patients aged 1 to \< 18 years old at the start of treatment with entresto exclusion criteria 1. patients who have received drugs containing the same ingredient as entresto (including investigational products and drugs for post-marketing clinical study) 2. patients for whom entresto is contraindicated according to the package insert * patients with a history of hypersensitivity to any ingredients of entresto * patients currently under treatment with angiotensin-converting enzyme inhibitors or within 36 hours of discontinuation of treatment with angiotensin-converting enzyme inhibitors (alacepril, imidapril hydrochloride, enalapril maleate, captopril, quinapril hydrochloride, cilazapril hydrate, temocapril hydrochloride, delapril hydrochloride, trandolapril, benazepril hydrochloride, perindopril erbumine, lisinopril hydrate). * patients with a history of angioedema (including angioedema due to angiotensin ii receptor blockers or angiotensin-converting enzyme inhibitors, hereditary angioedema, acquired angioedema, and idiopathic angioedema etc.) * patients with diabetes mellitus under treatment with aliskiren fumarate (excluding patients with markedly poorly controlled blood pressure despite other antihypertensive therapies) * patients with severe hepatic impairment (child-pugh class c) * pregnant women or women who may be pregnant
using urine color as a marker of hydration status

Conditions: Dehydration

Summary: the purpose of this study was to determine if rapid changes in hydration status could be determined by urine color expressed in cie color space

the study will examine if urine color expressed in cie color space can reflect hydration status. hydration staus will be rapidly altered via exercise in the heat.

Eligibility criteria:
inclusion criteria: * 18-35 years of age, * no previous heat intolerance exclusion criteria: - pregnant women,
can breathe in copd trial

Conditions: Chronic Obstructive Pulmonary Disease (COPD); Breathlessness; Exercise Intolerance

Summary: a growing body of physiological evidence now exists to support a potential role for inhaled cannabis in the medical management of adults with chronic obstructive pulmonary disease (copd), particularly as it may related to improving pulmonary function, alleviating the symptom of breathlessness and improving exercise endurance. the purpose of this randomized double-blind crossover trials is to evaluate the efficacy and physiological mechanism(s) of action of inhaled vaporized cannabis targeted to relief of physical activity-related breathlessness and exercise endurance in symptomatic patients with severe-to-very severe copd.


Eligibility criteria:
inclusion criteria: * gold stage iii or iv copd (i.e., post-β2-agonist fev1 of 50% predicted or less) * self-reported cigarette smoking history ≥10 pack yrs * currently taking long-acting beta-2 agonists and long-acting antimuscarinic agents (laba/lamas) with or without an inhaled corticosteroid * willing to abstain from cannabis smoking for ≥15 days prior to study participation (if applicable) * willing to abstain from non-study related cannabis smoking throughout the study period (if applicable) * no change in medication dosage or frequency of administration, with no exacerbations or hospitalizations in the preceding 4 weeks exclusion criteria: * presence of active and/or uncontrolled cardiopulmonary and/or musculoskeletal disease other than copd that could contribute to breathlessness and exercise intolerance * hepatic or renal impairment * psychiatric history (other than depression and/or anxiety) * history of epilepsy or convulsions; * lung cancer * history of sensitivity to cannabis * use of levodopa, sildenafil and/or fentanyl * use of ketoconazole * use of regular high dose opioids (i.e., 30 mg of oral morphine equivalents/day) * known or suspected history of addiction/substance abuse based on cage-aid and sisap scores (\*note, patients may be recruited if they have a history of smoking cannabis) * positive urine toxicology for cannabinoids on screening * positive pregnancy urine test * subject cannot arrange to be accompanied home by a family member and/or friend during each treatment visit.

Keywords: cannabis marijuana
heal-ist ide trial

Conditions: Inappropriate Sinus Tachycardia

Summary: inappropriate sinus tachycardia (ist) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. the primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant ist.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years and ≤ 75 years at time of enrollment consent 2. subject has a diagnosis of ist 3. documentation of refractoriness (intolerance or failure) of a drug (e.g., rate control drugs such as beta-blockers/calcium channel blockers, ivabradine), and/or aads 4. subject is willing and able to provide written informed consent exclusion criteria: 1. subjects on whom cardiac surgery or single lung ventilation cannot be performed 2. subjects with indication for or existing icds/pacemakers 3. presence of channelopathies 4. previous cardio-thoracic surgery 5. left ventricular ejection fraction (lvef) \< 50% 6. body mass index (bmi) ≥ 35 7. presence of supraventricular or ventricular tachycardia 8. presence of postural orthostatic sinus tachycardia (pots) 9. presence of congenital heart disease 10. history suggestive of secondary cause of tachycardia such as pheochromocytoma, anemia, thyrotoxicosis, chronic fever of unknown origin, copd, long-term bronchodilators use, severe asthma or carcinoid syndrome 11. subjects who have had a previous catheter ablation in the right atrium for ist or other disorders 12. life expectancy \< 24 months 13. pregnant or planning to become pregnant during trial 14. subjects with substance abuse 15. subjects with previous weight loss surgery 16. subject is unwilling and/or unable to return for scheduled follow-up visits 17. current participation in another clinical investigation of a medical device or a drug, or recent participation in such a trial that may interfere with trial results 18. not competent to legally represent him or herself (e.g., requires a guardian or caretaker as a legal representative) and; 19. presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
comparison of the concentration of estrogen and testosterone ratio in male patients with cirrhosis and hypotension

Conditions: Hypotension; Cirrhosis

Summary: cirrhosis is an end stage in liver disease leading to replacement of normal liver tissue with regenerative nodules surrounded by fibrous bands in response to chronic liver injury. it is the eighth leading cause of death in the united states and the thirteenth leading cause of death globally. patients with cirrhosis have decreased spontaneous vascular resistance leading to hypotension. the mechanism of hypotension in cirrhosis is thought to be a complex result of the presence of increased level of circulating vasodilators such a nitric oxide coupled with reduced resistance to vasoconstrictors and increased sensitivity to vasodilators.

another potential contributor to the development of hypotension in cirrhosis is thought to be due to the increased production of estrogen in males especially the estrone (e1) and estradiol (e2) concentration. the concentration of estrogen in cirrhotic patients is thought to increase by fourfold compared to individuals without cirrhosis. the increased estrogen concentration in cirrhosis patients results, in large part, from an increased peripheral conversion from androgens including testosterone. previous studies have shown that increased estrogen concentration can cause a significant decrease in blood pressure in various cell, animal, and human models. of note, estrogen has also been shown to enhance nitric oxide production in human beings.

Eligibility criteria:
inclusion criteria: * male cirrhotic patients \>18 years of age * patient must attend the outpatient clinic of the liver institute at methodist dallas medical center * willing to provide informed consent to participate in the study exclusion criteria: * patients with a history of cirrhosis \<18 years of age * cirrhosis patients with active infection * cirrhosis patients with active gastrointestinal bleeding * cirrhosis patients on hormone replacement therapy testosterone * cirrhosis patients on any antihypertensive medications
open and exploratory trial to investigate the pharmacokinetic of ceftobiprole medocaril in patients with csf device

Conditions: Inflamed Meninges; Suspected Meningitis; Ventriculitis

Summary: ceftobiprole is a very active new cephalosporin on staphylococci resistant to methicillin (semr: staphylococcus epidermidis resistant to meticillin, samr: staphylococcus aureus resistant to meticillin) and / or vancomycin; it is also very active on pneumococci resistant to penicillin and / or 3rd generation cephalosporins. this new drug has amm in nosocomial respiratory infections, animal work shows the efficacy of ceftobiprole in gram negative bacillus meningeal infections. the rationale of this study is based on the antibacterial spectrum of ceftobiprole, which would therefore be useful in the treatment of staphylococcal bacterial meningitis resistant patients (semr or samr) encountered in intensive care and / or neurosurgery and in the treatment of pneumococcal meningitis. to validate these possibilities, it is necessary to know the concentrations of ceftobiprole in the meningeal space.


Eligibility criteria:
inclusion criteria: * adult patients (\> 18 years) * provision of informed consent prior to any study specific procedures * female patients of childbearing potential may be entered if pregnancy testing is negative and the patient agrees to abstain from procreational sexual intercourse or must use double-barrier contraceptive measures for the duration of the study * presence of an indwelling external csf access device (ventriculostomy or lumbar drain) * presence of inflamed meninges as a result of documented or suspected meningitis or ventriculitis. patients with both clinical symptoms (fever, headache, meningismus, and altered mentation) and laboratory parameters (csf leukocytosis, defined as a csf white blood cell count \[wbc\] of \>103, elevated csf protein, defined as csf protein of \>1g/l, reduced csf glucose, defined as csf glucose of \ 5 leukocytes/mm3 of csf. * person with antibacterial treatment (including treatment for the current meningitis or ventriculitis) * glycemia above 3 mmol/l and below 10 mmol/l * natremia below 145 mmol/l * capnia below 45 mmhg * no other patient included within 72 hours from d0 (treatment period) of the previous patient * agreement of the scientific committee exclusion criteria: * hypersensitivity to mabelio® (ceftobiprole) or to one of its excipient or another 3rd cephalosporin * hypersensitivity to cephalosporin * immediate and severe hypersensitivity to β-lactam antimicrobial other than mabelio and other cephalosporins * pregnant or breast feeding women * renal insufficiency defined as creatinine clearance \< 50 ml/min * patient with creatinine clearance \> 150 ml/min * patients with conditions known or suspected to alter pharmacokinetics (i.e., burn or cystic fibrosis patients) * refusal to participate * person not affiliated to the social security * absolute necessity of immediate removing the device
nilotinib in adult patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase

Conditions: Chronic Myeloid Leukemia

Summary: multi-center, open-label, non-randomized trial to evaluate long-term safety and efficacy of nilotinib. approximately 20 patients will be enrolled in this trial at 3 centers in mexico, which means all ongoing patients participating on \[camn107a2109\] excluding discontinued patients. during this study, patients will receive nilotinib orally, at a dose of 400 mg b.i.d. patients will normally receive nilotinib on an outpatient basis. this trial will have a maximum of 24 months of follow-up time.


Eligibility criteria:
inclusion criteria: * having participated in novartis study camn107a2109, and * written signed and dated informed consent prior to any study procedures being performed. exclusion criteria: * impaired cardiac function, * use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon) up to the day before study drug administration; other concurrent severe and/or uncontrolled medical conditions, * patients who are currently receiving treatment with any of the medications that have the potential to prolong the qt interval, * patients who have undergone a major surgery and have not recovered from side effects of such therapy within 15 days, * patients who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control, or * patients unwilling or unable to comply with the protocol. other protocol -defined inclusion/exclusion criteria may apply

Keywords: chronic myeloid leukemia, blast crisis, accelerated phase, nilotinib, imatinib, resistant, intolerant, chronic phase
the individualized treatment of 6-mercaptopurine in children with acute lymphoblastic leukemia in china

Conditions: Acute Lymphoblastic Leukemia, Pediatric

Summary: the purpose of this study was to assess the efficacy and safety of individualized treatment of 6-mercaptopurine (6-mp) in chinese children with acute lymphoblastic leukemia, and to investigate the dose-concentration-response (der) relationship between thiopurine metabolites and adverse events. the individualized administration of 6-mp was established in chinese children with acute lymphoblastic leukemia.

to inflict minimal pain on the child contributing blood samples, opportunistic sampling design was chosen to collect pharmacokinetic samples.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of acute lymphoblastic leukemia; 2. age 1-18y at time of initial diagnosis; 3. eastern cooperative oncology group (ecog) performance status of 0-2 4. informed consent signed by the patients parents or guardians before initiation of the study. exclusion criteria: 1. ph-positive all, matrue b-cell all, bc-cml; 2. secondary to immunodeficiency, second cancer； 3. abnormal liver and kidney function; 4. patients divided into intermediate or high risk groups according to the risk grouping criteria of the chinese children cancer group (cccg) protocol-all 2015; 5. patients who enrolled in another clinical trial; 6. expected survival time less than the treatment cycle; 7. patients with other factors that researcher considers unsuitable for inclusion

Keywords: acute lymphoblastic leukemia 6-mercaptopurine children individualized treatment
effects of cervical stabilization exercise in violinists with chronic neck pain

Conditions: Neck Pain

Summary: the purpose of this study is to examine the influence of a 6-week cervical stabilization exercise program in university violin players with chronic nonspecific neck pain.


Eligibility criteria:
inclusion criteria: * duration of playing the instrument longer than 5 years * practicing the violin more than 5 hours/week * constant neck pain for more than 3 months or at least 2 pain episodes in the last 3 months exclusion criteria: * previous surgery in the neck and shoulder regions * current participation in a structured exercises program * current treatment for neck and shoulder pain * red flags suggesting of cancer, infection, vascular insufficiency, and etc. during history taking * neurological symptoms of the upper extremities during screening tests (e.g. spurling test and upper limb tension tests)

Keywords: cervical stabilization exercise
yoga intervention for reducing fatigue in cancer patients

Conditions: Fatigue; Cancer

Summary: cancer patients suffer from severe exhaustion and tiredness that is disproportionate to previous efforts and that cannot be completely reduced by sleep. the effectiveness of an 8 week yoga therapy (one hour a week) in patients with different cancer types on self-reported fatigue will be tested.

almost 90% of cancer patients suffer from symptoms of fatigue during treatment. supporting treatments are increasingly used to alleviate the burden of fatigue. this study examines the short-term effects of yoga on fatigue, depression and quality of life. the aim of this study will evaluate the efficacy of yoga for cancer patients with mixed diagnoses reporting fatigue. we will randomly allocate 124 patients to an intervention group (n=62) receiving yoga and a wait-list control group (n=62) receiving yoga 9 weeks later. the yoga therapy will be performed in weekly sessions of 60 minutes each for 8 weeks. the primary outcome will be self-reported fatigue symptoms. secondary outcome will be depression and quality of life

Eligibility criteria:
inclusion criteria: * oncological disease * planned to undergo cancer related treatment at radiotherapy outpatient clinic or the interdisciplinary oncological therapy outpatient clinic * reported fatigue symptoms: (intensity ≥4, impairment ≥ 5). exclusion criteria: * insufficient knowledge of german * severe emotional or physical impairment * more than 50km distance to the university hospital which would require travelling.

Keywords: yoga mindfulness based intervention fatigue cancer patients